Observational studyBMC infectious diseases2025
Comorbidities in hospitalized patients with herpes zoster: an Italian retrospective observational study in the years 2011-2023.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes Zoster (HZ) is caused by the reactivation of the varicella zoster virus (VZV). Although aging is the most well-known risk factor for herpes zoster, little is known about the strength of the association between patient-related characteristics, including comorbidities, and their contribution to an increased risk of mortality, among patients hospitalized for HZ. The aim of this study was to assess hospitalization trends and the strength of this association.
methodsThis retrospective population-based study, conducted among all patients hospitalized with HZ in Italy, between January 1st 2011 and December 31st 2023, analysed Hospital Discharge Records (HDR) reporting the ICD-9-CM codes related to HZ infection. Comorbidities that induce a reduced response of VZV-specific cell-mediated immunity - such as malignant neoplasms, chronic obstructive pulmonary disease, kidney diseases, diabetes mellitus, autoimmune diseases - were considered. Poisson regressions models, adjusted for age classes and sex, were used to identify factors associated with an increased risk of death.
resultsBetween 2011 and 2023, 47,933 hospitalizations with HZ were recorded. HZ comorbidities were diagnosed in 27.71% of cases (13,280 hospitalizations). The analysis revealed that the presence of neoplasms (IRR: 3.15; 95% C.I. 2.61-3.78) and kidney disease (IRR: 2.05; 95% C.I. 1.66-2.53) increased the risk of death among patients hospitalized with HZ. In the presence of comorbidities, males had a higher risk of death than females, and age was the strongest predictor. The risk increased significantly after the age of 40, reaching an IRR of 37.16 in patients over 80 years old with neoplasms.
conclusionsThe findings of this Real-World study may raise awareness of the risks associated with HZ and support vaccination efforts to prevent infection, particularly among older adults and individuals with comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.